Journal of Clinical Oncology, Vol 10, 282-291, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

BJ Roth, DH Johnson, LH Einhorn, LP Schacter, NC Cherng, HJ Cohen, J Crawford, JA Randolph, JL Goodlow and GO Broun
Department of Medicine, Indiana University School of Medicine, Indianapolis.

PURPOSE: The trial was undertaken to determine (1) the relative efficacy/toxicity of two commonly used combination chemotherapy regimens in patients with extensive small-cell lung cancer (SCLC) and (2) whether the rapid alternation of these two regimens could provide superior therapeutic results compared with either regimen alone. PATIENTS AND METHODS: In this phase III trial, 437 eligible patients were stratified by performance status (PS) and sex and were randomly assigned to receive either 12 weeks of cisplatin and etoposide (EP); 18 weeks of cyclophosphamide, doxorubicin, and vincristine (CAV); or 18 weeks of alternation of these two regimens (CAV/EP). RESULTS: There were no significant differences in treatment outcome for EP, CAV, or CAV/EP in terms of response rate (61%, 51%, 59%, respectively), complete response rate (10%, 7%, 7%, respectively), or median survival (8.6 months, 8.3 months, 8.1 months, respectively), with a non- statistically significant trend toward a longer median time to progression with alternating therapy (4.3 months, 4.0 months, 5.2 months, respectively). Crossover second-line chemotherapy given at progression produced low response rates and short survival, regardless of the regimen used. Myelosuppression was the dose-limiting toxicity for all patients, although the pattern and severity differed among the treatment arms. CONCLUSIONS: The combination regimens EP and CAV can be considered equivalently effective induction therapies in extensive SCLC, and these two regimens are, to some degree, crossresistant. Alternating therapy provides no therapeutic advantage compared with the use of either of these regimens alone and should not be considered as standard treatment in this clinical setting.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Ardizzoni, A. Favaretto, L. Boni, E. Baldini, F. Castiglioni, P. Antonelli, F. Pari, C. Tibaldi, A. M. Altieri, S. Barbera, et al. Platinum-Etoposide Chemotherapy in Elderly Patients With Small-Cell Lung Cancer: Results of a Randomized Multicenter Phase II Study Assessing Attenuated-Dose or Full-Dose With Lenograstim Prophylaxis--A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) Study J. Clin. Oncol., January 20, 2005; 23(3): 569 - 575. [Abstract] [Full Text] [PDF]

				S. Ramalingam, C. P. Belani, R. Day, B. A. Zamboni, S. A. Jacobs, and J. R. Jett Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer Ann. Onc., February 1, 2004; 15(2): 247 - 251. [Abstract] [Full Text] [PDF]

				E. Felip, R. Rosell, M. Domine, L. Santome, P. Garrido, A. Font, A. Carrato, J. Terrasa, C. Vadell, J. M. Mane, et al. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study Ann. Onc., October 1, 2003; 14(10): 1549 - 1554. [Abstract] [Full Text] [PDF]

				P.J. Hoskins, K.D. Swenerton, J.A. Pike, P. Lim, C. Aquino-Parsons, F. Wong, and N. Lee Small-Cell Carcinoma of the Cervix: Fourteen Years of Experience at a Single Institution Using a Combined-Modality Regimen of Involved-Field Irradiation and Platinum-Based Combination Chemotherapy J. Clin. Oncol., September 15, 2003; 21(18): 3495 - 3501. [Abstract] [Full Text] [PDF]

				I. Sekine, Y. Nishiwaki, K. Noda, S. Kudoh, M. Fukuoka, K. Mori, S. Negoro, A. Yokoyama, K. Matsui, Y. Ohsaki, et al. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI) Ann. Onc., May 1, 2003; 14(5): 709 - 714. [Abstract] [Full Text] [PDF]

				G. A. Masters, L. Declerck, C. Blanke, A. Sandler, R. DeVore, K. Miller, and D. Johnson Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597 J. Clin. Oncol., April 15, 2003; 21(8): 1550 - 1555. [Abstract] [Full Text] [PDF]

				W. West, R. Birch, F. Schnell, J. Hainsworth, J. Tongol, and L. Campos Phase I Study of Paclitaxel and Topotecan for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer Oncologist, February 1, 2003; 8(1): 76 - 82. [Abstract] [Full Text] [PDF]

				A. Ardizzoni, C. Manegold, C. Debruyne, R. Gaafar, E. Buchholz, E. F. Smit, P. Lianes, G. ten Velde, L. Bosquee, C. Legrand, et al. European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer Clin. Cancer Res., January 1, 2003; 9(1): 143 - 150. [Abstract] [Full Text] [PDF]

				D. H. Johnson "The Guard Dies, It Does Not Surrender!" Progress in the Management of Small-Cell Lung Cancer? J. Clin. Oncol., December 15, 2002; 20(24): 4618 - 4620. [Full Text] [PDF]

				S. Sundstrom, R. M. Bremnes, S. Kaasa, U. Aasebo, R. Hatlevoll, R. Dahle, N. Boye, M. Wang, T. Vigander, J. Vilsvik, et al. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years' Follow-Up J. Clin. Oncol., December 15, 2002; 20(24): 4665 - 4672. [Abstract] [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				S. H. Okuno and J. R. Jett Small Cell Lung Cancer: Current Therapy and Promising New Regimens Oncologist, June 1, 2002; 7(3): 234 - 238. [Abstract] [Full Text] [PDF]

				P. Bunn Reply to "Letter to the Editor on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'", by V. C. G. Tjan-Heijnen, P. E. Postmus & A. Ardizzoni (Ann Oncol 2002; 13: 485-486) Ann. Onc., March 1, 2002; 13(3): 486 - 487. [Full Text] [PDF]

				N. H. Hanna, A. B. Sandler, P. J. Loehrer Sr, R. Ansari, S. H. Jung, K. Lane, and L. H. Einhorn Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study Ann. Onc., January 19, 2002; 13(1): 95 - 102. [Abstract] [Full Text] [PDF]

				K. Noda, Y. Nishiwaki, M. Kawahara, S. Negoro, T. Sugiura, A. Yokoyama, M. Fukuoka, K. Mori, K. Watanabe, T. Tamura, et al. Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer N. Engl. J. Med., January 10, 2002; 346(2): 85 - 91. [Abstract] [Full Text] [PDF]

				K. Osterlind Chemotherapy in small cell lung cancer Eur. Respir. J., December 1, 2001; 18(6): 1026 - 1043. [Abstract] [Full Text] [PDF]

				K. Kelly, L. Lovato, P. A. Bunn Jr., R. B. Livingston, J. Zangmeister, S. A. Taylor, D. Roychowdhury, J. J. Crowley, and D. R. Gandara Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer: A Phase II Trial of the Southwest Oncology Group Clin. Cancer Res., August 1, 2001; 7(8): 2325 - 2329. [Abstract] [Full Text] [PDF]

				P. Thomas, O. Castelnau, D. Paillotin, H. Lena, G. Robinet, J. F. Muir, P. Delaval, S. Gouva, P. Balmes, F. Blanchon, et al. Phase II Trial of Paclitaxel and Carboplatin in Metastatic Small-Cell Lung Cancer: A Groupe Francais de Pneumo-Cancerologie Study J. Clin. Oncol., March 1, 2001; 19(5): 1320 - 1325. [Abstract] [Full Text] [PDF]

				H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF]

				T. T. Chen, J. P. Chute, E. Feigal, B. E. Johnson, and R. Simon A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer J Natl Cancer Inst, October 4, 2000; 92(19): 1601 - 1607. [Abstract] [Full Text] [PDF]

				K. Kelly New Chemotherapy Agents for Small Cell Lung Cancer Chest, April 1, 2000; 117(4_suppl_1): 156S - 162S. [Abstract] [Full Text] [PDF]

				D. H. Johnson Management of Small Cell Lung Cancer* : Current State of the Art Chest, December 1, 1999; 116(suppl_3): 525S - 530S. [Abstract] [Full Text] [PDF]

				S. Leyvraz, L. Perey, G. Rosti, A. Lange, S. Pampallona, R. Peters, Y. Humblet, L. Bosquee, F. Pasini, and M. Marangolo Multiple Courses of High-Dose Ifosfamide, Carboplatin, and Etoposide With Peripheral-Blood Progenitor Cells and Filgrastim for Small-Cell Lung Cancer: A Feasibility Study by the European Group for Blood and Marrow Transplantation J. Clin. Oncol., November 1, 1999; 17(11): 3531 - 3539. [Abstract] [Full Text] [PDF]

				H. Okamoto, K. Watanabe, Y. Nishiwaki, K. Mori, Y. Kurita, I. Hayashi, M. Masutani, K. Nakata, S. Tsuchiya, H. Isobe, et al. Phase II Study of Area Under the Plasma-Concentration-Versus-Time Curve-Based Carboplatin Plus Standard-Dose Intravenous Etoposide in Elderly Patients With Small-Cell Lung Cancer J. Clin. Oncol., November 1, 1999; 17(11): 3540 - 3545. [Abstract] [Full Text] [PDF]

				K. Kelly, Z. Pan, M. E. Wood, J. Murphy, and P. A. Bunn Jr. A Phase I Study of Paclitaxel, Etoposide, and Cisplatin in Extensive Stage Small Cell Lung Cancer Clin. Cancer Res., November 1, 1999; 5(11): 3419 - 3424. [Abstract] [Full Text] [PDF]

				B. S. Glisson, J. M. Kurie, R. Perez-Soler, N. J. Fox, W. K. Murphy, F. V. Fossella, J. S. Lee, M. B. Ross, D. A. Nyberg, K. M.W. Pisters, et al. Cisplatin, Etoposide, and Paclitaxel in the Treatment of Patients With Extensive Small-Cell Lung Carcinoma J. Clin. Oncol., August 1, 1999; 17(8): 2309 - 2309. [Abstract] [Full Text] [PDF]

				J. P. Chute, T. Chen, E. Feigal, R. Simon, and B. E. Johnson Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible Progress J. Clin. Oncol., June 1, 1999; 17(6): 1794 - 1794. [Abstract] [Full Text] [PDF]

				H. J.M. Groen, E. Fokkema, B. Biesma, B. Kwa, J. W.G. van Putten, P. E. Postmus, and E. F. Smit Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule J. Clin. Oncol., March 1, 1999; 17(3): 927 - 927. [Abstract] [Full Text] [PDF]

				J. von Pawel, J. H. Schiller, F. A. Shepherd, S. Z. Fields, J.P. Kleisbauer, N. G. Chrysson, D. J. Stewart, P. I. Clark, M. C. Palmer, A. Depierre, et al. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer J. Clin. Oncol., February 1, 1999; 17(2): 658 - 658. [Abstract] [Full Text] [PDF]